Search Results

OrbusNeich's Combo Stent Evaluated in All-Comers Pooled Patient Cohort

March 10, 2018—Antonio Colombo, MD, presented 1-year real-world performance outcomes from the COMBO Collaboration study at the American College of Cardiology's (ACC) 67th annual scientific session held March 10–12 in Orlando, Florida.

24-Month Data and Live Case Presented for Elixir Medical’s DynamX Bioadaptor

January 27, 2021—Elixir Medical announced the 24-month clinical results for the DynamX coronary bioadaptor system, a drug-eluting coronary artery implant that adapts to vessel physiology.

Two-Year Data Reported for Direct Flow Medical's TAVR System

May 19, 2015—Direct Flow Medical, Inc., announced that 2-year data from the DISCOVER CE Mark Trial, which studied the Direct Flow Medical transcatheter aortic valve replacement (TAVR) system, were presented by Antonio Colombo, MD, at the EuroPCR conference being held May 19–22 in Paris, France.

Diab8 Randomized Trial Will Evaluate Alvimedica's Cre8 Evo DES in Patients With Diabetes

June 4, 2018—At the EuroPCR 2018 conference held May 22–25 in Paris, France, Alvimedica Medical Technologies announced the design of the company's Diab8 diabetic drug-eluting stent (DES) trial.

Neovasc's Reducer Device Launched in Select European Countries

March 19, 2015—Neovasc Inc. announced that the Reducer device for the treatment of refractory angina has been introduced to select centers in Italy and will soon be available for routine use at additional sites in Germany, the United Kingdom, and Switzerland.

European Studies Begin for Essential Medical's Manta Large-Bore Vascular Closure Device

July 27, 2015—Essential Medical, Inc. announced that it has commenced European clinical studies using its Manta large-bore vascular closure device, which is designed to seal both 14-F and 18-F large-bore femoral punctures. The Manta device closes femoral arterial punctures made during cardiac catheterization procedures such as transcatheter aortic valve replacement, endovascular treatment of abdominal aortic aneurysms, ventricular assist, and balloon aortic valvuloplasty.

Boston Scientific's Omega Platinum Chromium Bare-Metal Stent Approved in EU

March 7, 2011—Boston Scientific Corporation (Natick, MA) announced that it has received CE Mark approval for the Omega platinum chromium (PtCr) bare-metal coronary stent system, the company's third-generation coronary stenting technology.

Boston Scientific's Promus Element Plus Launched in Europe

February 1, 2012—Boston Scientific Corporation (Natick, MA) announced the European market launch of the Promus Element Plus everolimus-eluting platinum chromium (PtCr) coronary stent system.

First Patient Enrolled in TRANSFORM-1 RCT of Concept Medical’s MagicTouch Sirolimus-Coated Balloon for Small Coronary Vessels

September 2, 2020—Concept Medical Inc. announced the enrollment of the first patient in the TRANSFORM-1 randomized clinical trial (RCT) of the treatment of small coronary vessels with percutaneous coronary intervention (PCI) using the company’s MagicTouch sirolimus-coated balloon.

Concept Medical Completes Enrollment in the ABILITY DIABETES-GLOBAL RCT

September 28, 2022—Concept Medical Inc. announced the completion of enrollment in the ABILITY DIABETES-GLOBAL randomized controlled trial (RCT) comparing the company’s sirolimus drug-eluting stent (DES), Abluminus DES+, with the Xience family of DES (Abbott) for percutaneous coronary intervention (PCI) in patients with diabetes mellitus (DM).

Trial Commences for Concept Medical’s MagicTouch SCB in Small Vessels

August 4, 2025—Concept Medical Inc. recently announced the commencement of the MAGICAL-SV trial, which will enroll 1,605 patients across the United States and Europe.